Alimera Sciences

Retinal Disease
is Our Focus

Moving the back of the eye to the forefront
of research and development.

Learn more about our goals »

ILUVIEN: Investigational Treatment for DME

ILUVIEN® Fluocinolone acetonide intravitreal insert .019 mg

ILUVIEN® has received its marketing authorization approval in Austria, France, Germany, Portugal, Spain and the United Kingdom and is going through the national phase in the approval process in Italy. Alimera Sciences is still seeking approval in the United States.

Learn more >

Diabetes is the leading cause of new cases of blindness in adults

DIABETES and
VISION LOSS

Diabetes is the leading cause of new cases of blindness in adults.

Learn More >

Latest News

View All Recent News »

Alimera Sciences Reports Second Quarter 2014 Financial Results

August 07, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced financial results for the second quarter ended June 30,...

Read More »

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Denmark For The Treatment Of Chronic Diabetic Macular Edema

July 31, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Danish Health and Medicines Authority has...

Read More »

Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Norway For The Treatment Of Chronic Diabetic Macular Edema

July 28, 2014 --  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Norwegian Medicines Evaluation Board has...

Read More »